Hyundai Pharmaceutical

Asia

ASLAN posts positive top-line varlitinib phase 2 data in breast cancer

ASLAN just rolled out positive top-line phase 2 data for its lead drug candidate varlitinib when combined with chemotherapy for the treatment of HER2-positive breast cancer.

Angus Liu Feb 16, 2017 10:30am